Core Viewpoint - A class action lawsuit has been filed against Allarity Therapeutics, Inc. for alleged violations of the Securities Exchange Act, specifically related to misleading statements about the company's regulatory submissions and the risks associated with them [1][2]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Allarity's securities between May 17, 2022, and July 19, 2024, and encourages them to contact the Schall Law Firm before November 12, 2024 [1]. - The complaint alleges that Allarity and its executives made false and misleading statements regarding the Dovitinib NDA and Dovitinib-DRP PMA, which increased the company's exposure to regulatory scrutiny [2]. - The company is accused of downplaying the likelihood of enforcement actions after an investigation was announced, leading to materially misleading public statements throughout the class period [2]. Group 2: Investor Participation - Investors are invited to join the class action to recover their losses, with the Schall Law Firm specializing in securities class action lawsuits and shareholder rights litigation [3].

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical development programsEli Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant Chief Medical Officer to drive the stenoparib program toward regulatory approvalFormer President of Novo Nordisk’s U.S. Operations, Jesper Høiland, appointed as Strategic Advisor to guide strategic initiatives and optimize commercial potential Boston (October 3, 2024) — Allarit ...

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

LOS ANGELES, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”). If you suffered a loss on your Allarity investments or would like to inquire about potentiall ...

SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Allarity Therapeutics, Inc. (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024. Allarity is a clinical-stage biopharmaceutical company that develops oncology therapeutics using drug-specific companion diagnostics generated by its Drug Response Predictor technology. For more information, submit a form, emai ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2024. SO WHAT: If you purchased Allarity securities during ...

NEWTOWN, Pa., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, announces the recent filing of a securities fraud class action on behalf of purchasers of Allarity Therapeutics, Inc. (NASDAQ: ALLR) common stock between May 17, 2022, and July 19, 2024, inclusive (the “Class Period”). A copy of the Complaint can be found HERE. Investors who purchased Allarity stock may move the U.S. District Court for the Southern District of New York to appoint them as lead plaintiff, n ...

NEW YORK, Sept. 18, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2024.So what: If you purchased Allarity securities during the Class ...